<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acanthosis nigricans
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acanthosis nigricans
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acanthosis nigricans
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrea D Maderal, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H561155440">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acanthosis nigricans is a common condition characterized by velvety, hyperpigmented plaques on the skin. Intertriginous sites, such as the neck and axillae, are common sites for involvement. Less frequently, acanthosis nigricans appears in other skin sites or on mucosal surfaces.
        </p>
        <p>
         Clinical recognition of acanthosis nigricans is important because the disorder can occur in association with a variety of systemic abnormalities, many of which are characterized by insulin resistance. Obesity and diabetes mellitus are among the most frequently associated disorders. Rarely, acanthosis nigricans develops as a sign of internal malignancy.
        </p>
        <p>
         The epidemiology, diagnosis, and treatment of acanthosis nigricans will be reviewed here. Specific disorders that may present with acanthosis nigricans are reviewed in greater detail separately.
        </p>
        <p class="headingAnchor" id="H561155447">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acanthosis nigricans can affect both males and females, as well as infants, children, and adults. Although prevalence rates of this disorder have varied among studies, it is evident that a significant proportion of individuals who are obese or diabetic exhibit this finding and that the prevalence of this disorder may differ among ethnic groups [
         <a href="#rid1">
          1-12
         </a>
         ].
        </p>
        <p>
         In a multiethnic cross-sectional study of 1730 patients aged 7 to 65 years seen in primary care settings in a variety of sites within the United States in 2007, 19 percent had acanthosis nigricans [
         <a href="#rid13">
          13
         </a>
         ]. Increasing obesity rates are a factor in the prevalence of acanthosis nigricans, notably in pediatric populations [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Obesity, endocrine, and metabolic disorders'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H464423">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acanthosis nigricans may be acquired or inherited. Most, if not all, patients with acanthosis nigricans have one of the following categories of disorders:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endocrine and metabolic disorders, particularly disorders associated with insulin resistance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic syndromes with acanthosis nigricans
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial acanthosis nigricans
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug reactions
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H464431">
         <span class="h2">
          Obesity, endocrine, and metabolic disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obesity and diabetes mellitus are the most common medical disorders linked with acanthosis nigricans [
         <a href="#rid1">
          1-3,5,8,15,16
         </a>
         ].
        </p>
        <p>
         Insulin resistance likely accounts for the development of acanthosis nigricans in individuals with these conditions (see
         <a class="local">
          'Pathogenesis'
         </a>
         below). In one study of 236 children with acanthosis nigricans and 51 overweight children without the disorder, significant associations of acanthosis nigricans with insulin resistance and abnormal glucose homeostasis were detected [
         <a href="#rid17">
          17
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">
          "Insulin resistance: Definition and clinical spectrum"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obesity
         </strong>
         – The link between acanthosis nigricans and weight was demonstrated in a study of 1133 young patients from multiple communities in the United States in which the prevalence of acanthosis nigricans increased with rising body mass index (BMI) [
         <a href="#rid11">
          11
         </a>
         ]. Among subjects aged 7 to 19 years who were of normal weight, overweight, or obese, acanthosis nigricans was detected in 3, 11, and 51 percent, respectively. An increase in acanthosis nigricans with rising weight was also evident among slightly older subjects (ages 20 to 39 years); 3, 12, and 37 percent of subjects in the respective weight groups within this population were affected. Concordantly, a smaller practice-based study found a high rate of acanthosis nigricans in children who were obese [
         <a href="#rid10">
          10
         </a>
         ]. Among children aged 7 to 17 years with a BMI that met or exceeded the 98
         <sup>
          th
         </sup>
         percentile, 62 percent had the skin condition. (See
         <a class="medical medical_review" href="/z/d/html/5356.html" rel="external">
          "Measurement of growth in children", section on 'Body mass index'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes
         </strong>
         – Type 2 diabetes mellitus is also strongly associated with acanthosis nigricans [
         <a href="#rid2">
          2,6,11,13,15
         </a>
         ]. In the study of 1133 patients mentioned above, type 2 diabetes was present in 15 percent of patients with acanthosis nigricans, compared with 4 percent of patients without the skin condition [
         <a href="#rid11">
          11
         </a>
         ]. After controlling for age, BMI, and number of diabetes risk factors, patients with acanthosis nigricans were twice as likely to have type 2 diabetes as unaffected individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, a practice-based study with 1730 patients supported the association between type 2 diabetes and acanthosis nigricans [
         <a href="#rid13">
          13
         </a>
         ]. Type 2 diabetes was present in 35 versus 18 percent of patients with or without acanthosis nigricans, respectively. Significantly higher serum levels of insulin were also detected in the patients with acanthosis nigricans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The prevalence of acanthosis nigricans in a population of patients with newly diagnosed type 2 diabetes was evaluated in a study of 216 adults in Texas in 1998 and 1999. In the study, acanthosis nigricans was detected in 36 percent [
         <a href="#rid6">
          6
         </a>
         ]. The likelihood of having acanthosis nigricans increased with the degree of obesity, with over 50 percent of individuals with a BMI ≥30 mg/m
         <sup>
          2
         </sup>
         demonstrating the disorder. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5372.html" rel="external">
          "Obesity in adults: Prevalence, screening, and evaluation", section on 'Body mass index'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polycystic ovarian syndrome
         </strong>
         – Polycystic ovarian syndrome (PCOS) is associated with insulin resistance and hyperinsulinemia, and studies suggest that 5 to 37 percent of women with PCOS have acanthosis nigricans [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among women with PCOS, acanthosis nigricans may be a marker of increased risk for endocrine and metabolic abnormalities. A retrospective study of 401 women with suspected PCOS found that among women who met diagnostic criteria for PCOS, the presence of acanthosis nigricans was associated with higher rates of elevated free
         <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">
          testosterone
         </a>
         levels, insulin resistance, dyslipidemia, and increased body mass index [
         <a href="#rid20">
          20
         </a>
         ]. In addition, a study of 339 women with PCOS and normal BMI found acanthosis nigricans significantly associated with insulin resistance and reduced high-density lipoprotein cholesterol [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other disorders
         </strong>
         – In a 2007 cohort of middle-aged Sri Lankan adults, acanthosis nigricans was present in 296 of 1025 subjects with metabolic syndrome (29 percent) and only 217 of 1924 subjects without the syndrome (11 percent) [
         <a href="#rid2">
          2
         </a>
         ]. In addition, hypertension and dyslipidemia, components of the metabolic syndrome, have been linked to acanthosis nigricans in children [
         <a href="#rid16">
          16,17,22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples of other metabolic or endocrine disorders associated with acanthosis nigricans include acromegaly and Cushing's syndrome [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H464447">
         <span class="h2">
          Genetic syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple genetic disorders have been associated with acanthosis nigricans, many of which are characterized by insulin resistance that results either from defects in the insulin receptor or the production of antibodies against the insulin receptor. Acanthosis nigricans is a clinical feature that can aid in the recognition of these genetic diseases [
         <a href="#rid26">
          26
         </a>
         ]. Some, but not all, patients with acanthosis nigricans with onset in infancy or early childhood, develop the condition as a feature of a genetic disorder [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         Examples of genetic syndromes characterized by insulin resistance that can present with acanthosis nigricans include Down syndrome, leprechaunism, Rabson-Mendenhall syndrome, congenital generalized lipodystrophy (Berardinelli-Seip syndrome), familial partial lipodystrophy, and Alstrom syndrome [
         <a href="#rid28">
          28,29
         </a>
         ]. Cutis gyrata syndrome, Crouzon syndrome with acanthosis nigricans, thanatophoric dysplasia, Costello syndrome, and severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) are additional genetic syndromes that are not characterized by insulin resistance but may also present with acanthosis nigricans [
         <a href="#rid28">
          28,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">
          "Insulin resistance: Definition and clinical spectrum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Congenital generalized lipodystrophy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Familial partial lipodystrophy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2942.html" rel="external">
          "Craniosynostosis syndromes", section on 'Crouzon syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14209.html" rel="external">
          "Approach to prenatal diagnosis of the lethal (life-limiting) skeletal dysplasias", section on 'Thanatophoric dysplasia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H332799">
         <span class="h2">
          Familial
         </span>
         <span class="headingEndMark">
          —
         </span>
         Documentation of familial, noninsulin resistance-related, nonsyndromic forms of acanthosis nigricans are limited to reports of a few families and involve mutations in FGFR3 (fibroblast growth factor receptor 3) [
         <a href="#rid27">
          27,31
         </a>
         ]. The inheritance pattern is usually autosomal dominant, and the clinical findings are typically first detected in infancy. A Pakistani family with isolated familial acanthosis nigricans with an autosomal recessive inheritance pattern has been reported [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H464455">
         <span class="h2">
          Malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, acanthosis nigricans occurs as a paraneoplastic disorder [
         <a href="#rid33">
          33-35
         </a>
         ]. Abdominal adenocarcinomas, particularly gastric adenocarcinomas, represent the majority of acanthosis nigricans-associated tumors [
         <a href="#rid35">
          35-39
         </a>
         ]. Mucosal and cutaneous papillomatosis can be a unique presenting sign of malignant acanthosis nigricans [
         <a href="#rid40">
          40
         </a>
         ]. Patients may concurrently develop the sign of Leser-Trélat or tripe palms, which are additional cutaneous disorders that can occur in association with internal malignancy. (See
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Acanthosis nigricans'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Tripe palm'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Sign of Leser-Trélat'
         </a>
         .)
        </p>
        <p>
         Malignancy-associated acanthosis nigricans is extremely rare in children. Several cases in which children developed acanthosis nigricans in conjunction with gastric adenocarcinoma, Wilms' tumor, or osteogenic sarcoma have been documented [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H464810">
         <span class="h2">
          Medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infrequently, acanthosis nigricans develops as a side effect of drug exposure. This most commonly occurs in the setting of medications that promote hyperinsulinemia. Medications that have been associated with acanthosis nigricans include systemic glucocorticoids [
         <a href="#rid33">
          33
         </a>
         ], injected insulin [
         <a href="#rid41">
          41
         </a>
         ], oral contraceptives [
         <a href="#rid42">
          42
         </a>
         ],
         <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">
          niacin
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ], protease inhibitors [
         <a href="#rid44">
          44
         </a>
         ],
         <a class="drug drug_general" data-topicid="10161" href="/z/d/drug information/10161.html" rel="external">
          palifermin
         </a>
         (a recombinant human keratinocyte growth factor used to manage severe chemotherapy-induced mucositis) [
         <a href="#rid45">
          45,46
         </a>
         ],
         <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">
          testosterone
         </a>
         [
         <a href="#rid47">
          47
         </a>
         ], and
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H561155454">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathways that lead to acanthosis nigricans are not well understood. Abnormalities involving three types of tyrosine kinase receptors, insulin-like growth factor receptor-1 (IGFR1), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR), have been proposed as potential contributing factors [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The association of acanthosis nigricans with multiple disorders characterized by insulin resistance suggests that hyperinsulinemia plays a key role in the development of acanthosis nigricans. Elevated levels of insulin may stimulate keratinocyte and dermal fibroblast proliferation via interaction with IGFR1, resulting in the plaque-like lesions that typify the disorder [
         <a href="#rid28">
          28
         </a>
         ]. Acanthosis nigricans related to genetic syndromes of insulin resistance, obesity, diabetes mellitus, or other disorders associated with insulin resistance may be attributable to this theory (see
         <a class="local">
          'Etiology'
         </a>
         above). These theories are supported by the finding of inherited form of acanthosis nigricans due to a homozygous mutation in the insulin receptor gene [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Other mechanisms may also be involved in acanthosis nigricans, particularly in cases in which insulin resistance is absent. As an example, mutations in certain FGFRs may contribute to acanthosis nigricans through the promotion of keratinocyte proliferation and survival [
         <a href="#rid28">
          28
         </a>
         ]. Activating mutations in FGFR3 have been linked to several inherited syndromes that present with acanthosis nigricans, including Crouzon syndrome, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), thanatophoric dwarfism, and hypochondroplasia [
         <a href="#rid27">
          27,49
         </a>
         ]. In addition, FGFR3 mutations were identified in a family with familial acanthosis nigricans [
         <a href="#rid27">
          27,31
         </a>
         ], and at least two patients with malignancy-associated skin lesions [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Transforming growth factor (TGF)-alpha, a cytokine that may exert proliferative effects via activation of EGFR, may also contribute to the development of malignancy-associated acanthosis nigricans [
         <a href="#rid51">
          51,52
         </a>
         ]. In support of this theory is a report of a patient in whom reduction of elevated serum TGF-alpha levels and amelioration of acanthosis nigricans followed the removal of a malignancy [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         The mechanisms by which other forms of acanthosis nigricans occur remain elusive. The predominant distribution of acanthosis nigricans in skin folds suggests a contributory role for friction or irritation in the disorder, but this has not been scientifically proven.
        </p>
        <p class="headingAnchor" id="H561155461">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acanthosis nigricans typically presents with thickened, velvety to verrucous, gray-brown, hyperpigmented plaques on the skin. The back of the neck, sides of the neck, and axillae are the most common sites of involvement  (
         <a class="graphic graphic_picture graphicRef72964 graphicRef52948 graphicRef66384 graphicRef81693 graphicRef61666" href="/z/d/graphic/72964.html" rel="external">
          picture 1A-E
         </a>
         ). Other intertriginous areas, such as the anogenital region and the inframammary, abdominal, antecubital, and inguinal skin folds, are less frequently affected  (
         <a class="graphic graphic_picture graphicRef76234" href="/z/d/graphic/76234.html" rel="external">
          picture 2
         </a>
         ). Additionally, severe cases may demonstrate lesions on the areola, perineum, umbilicus, lips, buccal or other mucosa, and other nonintertriginous areas  (
         <a class="graphic graphic_picture graphicRef50592 graphicRef63422 graphicRef52056" href="/z/d/graphic/50592.html" rel="external">
          picture 3A-C
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         In mild or early acanthosis nigricans, affected skin has a dirty appearance and a rough or dry texture with minimal plaque-like elevation. As the lesions progress, the skin becomes thicker and demonstrates accentuation of dermatoglyphics (skin lines) and papillomatous projections. Acrochordons (skin tags) may be present within or around affected areas  (
         <a class="graphic graphic_picture graphicRef61666" href="/z/d/graphic/61666.html" rel="external">
          picture 1E
         </a>
         ). Unlike cutaneous lesions, mucosal acanthosis nigricans usually does not demonstrate hyperpigmentation.
        </p>
        <p>
         Acanthosis nigricans typically develops in a symmetrical distribution. Unilateral cases of acanthosis nigricans may instead represent a variant of epidermal nevus [
         <a href="#rid53">
          53-56
         </a>
         ].
        </p>
        <p>
         An acral form of acanthosis nigricans, characterized by hyperpigmented plaques on the knuckles of the hands, elbows, knees, or feet and most commonly seen in individuals from sub-Saharan Africa, has also been described  (
         <a class="graphic graphic_picture graphicRef70582" href="/z/d/graphic/70582.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid14">
          14,33,57
         </a>
         ]. The term acral acanthotic anomaly has been used to refer to these lesions [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Acanthosis nigricans is usually asymptomatic. However, lesions in skin folds that become macerated and inflamed may become uncomfortable or malodorous. In particular, this may occur in the setting of secondary bacterial colonization or yeast infection.
        </p>
        <p class="headingAnchor" id="H1019361">
         <span class="h2">
          Malignancy-associated acanthosis nigricans
         </span>
         <span class="headingEndMark">
          —
         </span>
         The paraneoplastic form of acanthosis nigricans is most frequently diagnosed in older individuals and patients often are not obese. The lesions can arise before or after the detection of malignancy. In some cases, the diagnosis of acanthosis nigricans predates recognition of the malignancy by years [
         <a href="#rid38">
          38,59,60
         </a>
         ].
        </p>
        <p>
         Features that suggest the possibility of an underlying malignancy in a patient with acanthosis nigricans include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid onset of skin lesions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional paraneoplastic findings (eg, rapid growth or inflammation of seborrheic keratoses [the sign of Leser-Trélat] or the presence of tripe palms)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesions in atypical sites (eg, mucous membranes, palms, or soles)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained weight loss
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older adult
        </p>
        <p>
        </p>
        <p>
         Malignancy-associated acanthosis nigricans may be accompanied by localized or generalized pruritus and cutaneous and mucosal papillomatosis [
         <a href="#rid33">
          33,40
         </a>
         ]. In addition, other paraneoplastic dermatoses may occur with malignancy-associated acanthosis nigricans, such as velvety to rugose thickening of the palmar skin (tripe palms)  (
         <a class="graphic graphic_picture graphicRef61955" href="/z/d/graphic/61955.html" rel="external">
          picture 5
         </a>
         ) and the eruptive onset of multiple seborrheic keratoses (sign of Leser-Trélat) [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Acanthosis nigricans'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Tripe palm'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Sign of Leser-Trélat'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H561155468">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkeratosis and epidermal papillomatosis are the major pathologic features, and acanthosis is relatively mild. The hyperkeratosis is primarily responsible for the clinical finding of cutaneous hyperpigmentation; however, increased melanin in the basal layer of the epidermis also is sometimes detected [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         The dermis may demonstrate a mild infiltrate with lymphocytes, plasma cells and, occasionally, a few neutrophils. However, inflammation is not a prominent feature. Biopsies of mucosal lesions exhibit mild parakeratosis with epidermal hyperplasia and papillomatosis [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         The histologic features of acanthosis nigricans are consistent among the various forms of the condition. For example, microscopy cannot be used to distinguish paraneoplastic acanthosis nigricans from other types of acanthosis nigricans.
        </p>
        <p class="headingAnchor" id="H561155475">
         <span class="h1">
          DIAGNOSIS AND PATIENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical examination is usually sufficient to establish a diagnosis of acanthosis nigricans. In the rare cases in which the diagnosis is uncertain, a skin biopsy can be performed to confirm the clinical impression. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
         Due to the association of acanthosis nigricans with other abnormalities, the assessment for signs or symptoms of other disorders is an important component of the evaluation of affected patients [
         <a href="#rid64">
          64
         </a>
         ]. In general, we proceed with the following work-up in children and adults with acanthosis nigricans:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient history
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Age of onset
         </strong>
         – Onset in infancy or early childhood suggests the possibility of a syndromic or familial disorder, and malignancy-associated acanthosis nigricans is more common in adults than in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          History or symptoms suggestive of an underlying endocrinopathy
         </strong>
         – This information may help to identify the presence of type 2 diabetes, polycystic ovarian syndrome, acromegaly, Cushing's syndrome, or other endocrine disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Family history of acanthosis nigricans
         </strong>
         – In the absence of other underlying causes, may suggest familial acanthosis nigricans.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Possible exposure to drugs that may induce acanthosis nigricans
         </strong>
         (see
         <a class="local">
          'Medications'
         </a>
         above).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Height and weight
         </strong>
         – Used to establish the presence or absence of obesity, a common cause of acanthosis nigricans.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Growth rate in children
         </strong>
         – Abnormal growth may suggest the presence of an endocrinopathy or genetic syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physical signs suggestive of an underlying endocrinopathy
         </strong>
         – May help to identify the presence of type 2 diabetes, polycystic ovarian syndrome, acromegaly, Cushing's syndrome, or other endocrine disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Blood pressure assessment
         </strong>
         – Assesses for hypertension, which may occur at increased frequency in patients with acanthosis nigricans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory studies
         </strong>
         –
         <strong>
         </strong>
         Patients with acanthosis nigricans should be evaluated for the possibility of diabetes mellitus (see
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus", section on 'Screening tests'
         </a>
         ). Additional laboratory studies and other investigational tests are ordered based upon the findings on history and physical examination and suspicion for specific disorders. For example, women with features that suggest polycystic ovarian syndrome should be evaluated for this condition. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">
          "Insulin resistance: Definition and clinical spectrum", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The possibility of an occult malignancy should always be considered in adults who are older, nonobese, and with new-onset acanthosis nigricans without another identifiable cause and/or clinical features suggestive of malignancy-associated acanthosis nigricans (see
         <a class="local">
          'Malignancy-associated acanthosis nigricans'
         </a>
         above). However, there is little consensus on the appropriate cancer evaluation in such patients. At minimum, patients should be evaluated with a thorough review of symptoms, a complete physical examination, and age-appropriate cancer screening. Because many of the associated tumors involve the gastrointestinal tract, referral to gastroenterology is indicated.
        </p>
        <p class="headingAnchor" id="H561155482">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple other cutaneous disorders share features with acanthosis nigricans. The possibility of such disorders should be considered in patients with lesions that are not classic for acanthosis nigricans:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confluent and reticulated papillomatosis of Gougerot and Carteaud
         </strong>
         – This is an uncommon disorder that typically affects young adults. Reticulated, hyperpigmented, and slightly scaly plaques occur on the neck, chest (especially inframammary chest), and upper back  (
         <a class="graphic graphic_picture graphicRef67566 graphicRef76296" href="/z/d/graphic/67566.html" rel="external">
          picture 6A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Granular parakeratosis
         </strong>
         – Granular parakeratosis is a disorder characterized by the appearance of hyperkeratotic brown-red papules that coalesce to form plaques  (
         <a class="graphic graphic_picture graphicRef73591" href="/z/d/graphic/73591.html" rel="external">
          picture 7
         </a>
         ). Although the axilla is the most common site for involvement, the disorder may also occur in other intertriginous sites. Pruritus is typically present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lichen planus pigmentosus
         </strong>
         – Lichen planus pigmentosus is an uncommon variant of lichen planus that predominantly affects individuals with skin phototypes III and IV  (
         <a class="graphic graphic_table graphicRef60541" href="/z/d/graphic/60541.html" rel="external">
          table 1
         </a>
         ). The inverse form of lichen planus pigmentosus presents with hyperpigmented macules and patches in intertriginous areas  (
         <a class="graphic graphic_picture graphicRef111255" href="/z/d/graphic/111255.html" rel="external">
          picture 8
         </a>
         ). Some patients will also display typical lesions of lichen planus on other sites. (See
         <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">
          "Acquired hyperpigmentation disorders", section on 'Lichen planus pigmentosus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Linear epidermal nevus
         </strong>
         –
         <strong>
         </strong>
         Epidermal nevi are benign hamartomatous growths that are usually present at birth or become evident during the first year of life. The skin lesions are well-defined and often linear hyperpigmented, papillomatous plaques  (
         <a class="graphic graphic_picture graphicRef64855" href="/z/d/graphic/64855.html" rel="external">
          picture 9
         </a>
         ). Epidermal nevi may become more prominent over time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reticulated pigmented anomaly of the flexures (Dowling-Degos disease)
         </strong>
         – This is a rare, autosomal dominant disorder that presents with reticulated hyperpigmentation that has a predilection for flexural areas  (
         <a class="graphic graphic_picture graphicRef77681" href="/z/d/graphic/77681.html" rel="external">
          picture 10
         </a>
         ). Lesions typically appear in early adulthood. Some patients also exhibit comedones and pitted facial scars.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nevoid acanthosis nigricans (NAN) or rounded and velvety epidermal nevus (RAVEN)
         </strong>
         – NAN/RAVEN is a rare disorder that has a similar appearance to acanthosis nigricans; however, it is typically unilateral or localized and appears in childhood with an initial period of activity followed by stability without resolution. There are no systemic associations. It can be inherited as an autosomal dominant trait, and mutations in fibroblast growth factor receptor 3 (FGFR3) have been identified [
         <a href="#rid65">
          65-67
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other diagnostic considerations include pregnancy-associated hyperkeratosis of the nipple [
         <a href="#rid68">
          68
         </a>
         ], Hailey-Hailey disease  (
         <a class="graphic graphic_picture graphicRef61689 graphicRef80862 graphicRef74552" href="/z/d/graphic/61689.html" rel="external">
          picture 11A-C
         </a>
         ) (which is distinguished by the presence of inflammatory and erosive intertriginous plaques), pellagra (which can present with hyperpigmented plaques on the neck and other sun-exposed areas), and cutaneous hyperpigmentation related to Addison's disease.
        </p>
        <p class="headingAnchor" id="H561155489">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although acanthosis nigricans is a benign, often asymptomatic disorder, the appearance of acanthosis nigricans is a concern for some patients, prompting a desire for treatment. Treatment of the underlying cause, when feasible, is the preferred method of management, and obesity-related, drug-induced, and malignancy-associated acanthosis nigricans appear to frequently respond well to this intervention. In contrast, the likelihood for clinically significant improvement in acanthosis nigricans following the treatment of insulin resistant states is less certain [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         For patients in whom reversal of the underlying cause of acanthosis nigricans is impossible, in whom the degree of improvement is unsatisfactory, or who desire accelerated improvement in the cosmetic appearance of lesions, topical therapies that normalize epidermal proliferation, such as topical retinoids and topical vitamin D analogs, may be of benefit. Systemic retinoids have also been utilized for this indication but are not indicated for the treatment of most patients.
        </p>
        <p>
         Patient with acanthosis nigricans sometimes attempt to improve the appearance of lesions through excessive scrubbing of the affected skin during bathing. Such behavior should be discouraged, since it may result in lichenification (thickening of the skin) and worsening hyperpigmentation.
        </p>
        <p class="headingAnchor" id="H1018712">
         <span class="h2">
          Treatment of underlying disorders
         </span>
        </p>
        <p class="headingAnchor" id="H1018719">
         <span class="h3">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight loss has been linked to improvements in acanthosis nigricans in patients who are obese, including children [
         <a href="#rid70">
          70-72
         </a>
         ]. We support and encourage weight loss efforts in patients with obesity-related acanthosis nigricans. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15848.html" rel="external">
          "Prevention and management of childhood obesity in the primary care setting"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1018726">
         <span class="h3">
          Insulin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agents that improve insulin sensitivity, such as
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          rosiglitazone
         </a>
         , and other agents, may have some benefit for acanthosis nigricans related to insulin resistance [
         <a href="#rid69">
          69,73-80
         </a>
         ]. A small, unblinded, non-placebo-controlled, 12-week, randomized trial that compared metformin with rosiglitazone in patients who were overweight and obese and had acanthosis nigricans found no significant change in lesion severity and only modest improvement in skin texture [
         <a href="#rid74">
          74
         </a>
         ]. A 12-week, randomized trial that compared the effects of metformin with a product containing alpha-lipoic acid (an antioxidant associated with improvement in glucose metabolism),
         <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">
          biotin
         </a>
         , calcium, pantothenate, and
         <a class="drug drug_general" data-topicid="10328" href="/z/d/drug information/10328.html" rel="external">
          zinc sulfate
         </a>
         in 33 patients with acanthosis nigricans on the neck found similar, statistically significant reductions in acanthosis nigricans severity in the two groups [
         <a href="#rid80">
          80
         </a>
         ]. In an uncontrolled study, subjective improvement in acanthosis nigricans was noted in three out of five adolescents and adults with insulin resistance or diabetes who were treated with metformin for six months [
         <a href="#rid75">
          75
         </a>
         ]. Additional studies are necessary to explore the efficacy and safety of such agents in the treatment of acanthosis nigricans.
        </p>
        <p class="headingAnchor" id="H1018733">
         <span class="h3">
          Drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications associated with the onset of acanthosis nigricans should be discontinued if medically feasible. Discontinuation of the inciting drug often results in the resolution of the skin lesions [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Medications'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1018740">
         <span class="h3">
          Malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of the underlying malignancy is the preferred therapeutic intervention for patients with malignancy-associated acanthosis nigricans. Improvement or resolution of acanthosis nigricans has been reported in multiple patients following successful treatment of the associated malignancy [
         <a href="#rid14">
          14,37-39,81-84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1019164">
         <span class="h3">
          Other interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other therapies that have been associated with improvement of acanthosis nigricans in isolated patients include
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         in an adolescent who was obese [
         <a href="#rid85">
          85
         </a>
         ] and fish oil supplementation in a patient with a lipodystrophic form of diabetes [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H807895">
         <span class="h2">
          Skin-directed therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on the efficacy of therapies aimed at directly improving the skin lesions of acanthosis nigricans are limited to case reports and documentation of clinical experience. Although improvement has been reported with several topical and systemic agents, the optimal approach to treatment, the likelihood for treatment success, and the long-term efficacy of these interventions remains unknown.
        </p>
        <p>
         Topical agents, such as topical retinoids, vitamin D analogs, and keratolytics are the primary agents used in the treatment of localized lesions. Topical therapy is impractical for the management of patients with widespread involvement, and treatment options for this population are limited:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical retinoids
         </strong>
         – Retinoids have keratinolytic effects on the skin, and topical retinoid therapy has been linked to improvement in acanthosis nigricans in a small, split-neck, randomized trial that compared tretinoin 0.025% cream with
         <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">
          adapalene
         </a>
         0.1% gel for the treatment of pediatric acanthosis nigricans as well as case reports [
         <a href="#rid87">
          87-89
         </a>
         ]. The randomized trial found similar efficacy of tretinoin and adapalene.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Combination therapy with tretinoin and other agents may also be effective. Once-daily application of tretinoin 0.05% cream and twice-daily application of 12%
         <a class="drug drug_general" data-topicid="10073" href="/z/d/drug information/10073.html" rel="external">
          ammonium lactate
         </a>
         cream or lotion for a few months was associated with improvement in acanthosis nigricans on the front of the neck in a series of five patients [
         <a href="#rid90">
          90
         </a>
         ]. Of note, improvement was not detected on the sides of the neck, which were treated with either agent as monotherapy. In addition, a triple combination cream containing tretinoin 0.05%,
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         4%, and
         <a class="drug drug_general" data-topicid="8458" href="/z/d/drug information/8458.html" rel="external">
          fluocinolone
         </a>
         acetonide 0.01% applied daily for one month was effective in a patient with limited neck and face lesions [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical vitamin D analogs
         </strong>
         – Topical vitamin D analogs are capable of reducing keratinocyte proliferation and have been associated with lesion improvement in several patients [
         <a href="#rid73">
          73,92,93
         </a>
         ]. As an example,
         <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">
          calcipotriol
         </a>
         (calcipotriene) 0.005% cream applied twice daily for three months led to improvement in acanthosis nigricans in flexural areas in a male who was obese and had bladder cancer [
         <a href="#rid92">
          92
         </a>
         ]. Moreover, twice-daily use of calcipotriol ointment for four weeks by a man with hypogonadism-associated acanthosis nigricans was associated with complete remission of the lesions [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Skin irritation is a potential adverse effect of topical retinoids and topical vitamin D analogs.
        </p>
        <p>
         Other local therapies that have been suggested for the treatment of acanthosis nigricans include topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         , salicylic acid,
         <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">
          trichloroacetic acid
         </a>
         , glycolic acid peels, and laser therapy [
         <a href="#rid14">
          14,94-96
         </a>
         ]. A randomized trial (n = 38) in which patients with acanthosis nigricans were randomly assigned to treatment with either tretinoin 0.025% cream once daily or urea 10% cream twice daily found improvement in skin hyperpigmentation with both therapies [
         <a href="#rid97">
          97
         </a>
         ]. However,
         <a class="drug drug_general" data-topicid="10014" href="/z/d/drug information/10014.html" rel="external">
          topical tretinoin
         </a>
         demonstrated greater efficacy. In addition, fractional 1550 nm erbium laser was more effective for improving skin roughness than tretinoin 0.05% cream in a split-neck, randomized trial with 18 patients with acanthosis nigricans [
         <a href="#rid98">
          98
         </a>
         ]. Improvement in axillary acanthosis nigricans in a patient treated with long-pulsed alexandrite laser therapy has been reported [
         <a href="#rid94">
          94
         </a>
         ]. Greater than 95 percent clearance of the lesions was observed after five to seven treatments.
        </p>
        <p>
         Treatment with systemic retinoids such as
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         and
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         has been associated with moderate to marked improvement in several patients with extensive acanthosis nigricans [
         <a href="#rid73">
          73,76,99,100
         </a>
         ]. However, systemic retinoids have a wide range of potential adverse effects, and relapse appears to be common upon tapering or discontinuation of therapy [
         <a href="#rid73">
          73,76
         </a>
         ]. Treatment with these agents is not indicated in most patients.
        </p>
        <p>
         Case reports have documented beneficial effects of pharmacologic interventions in small numbers of patients with malignancy-associated acanthosis nigricans [
         <a href="#rid101">
          101,102
         </a>
         ]. A reduction in pruritus was noted in a lung cancer patient with treated psoralen plus ultraviolet A (PUVA) phototherapy [
         <a href="#rid101">
          101
         </a>
         ], and marked improvement in signs and symptoms of the disorder was reported in a patient with both gastric and prostate cancer who was treated with
         <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">
          cyproheptadine
         </a>
         [
         <a href="#rid102">
          102
         </a>
         ]. One case of improvement with
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         a glucagon-like peptide 1 (GLP-1) analog has been reported [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H324473">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acanthosis nigricans is a chronic disorder that persists in the absence of removal of the underlying cause or successful skin-directed therapy. In isolation, the long-term persistence of acanthosis nigricans usually has no physical adverse consequences.
        </p>
        <p>
         However, patients with acanthosis nigricans associated with obesity or medical disorders are subject to disease-specific sequelae. The prognosis for malignancy-associated acanthosis nigricans often is poor since malignancy is frequently diagnosed at an advanced stage [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H335766">
         <span class="h1">
          INDICATIONS FOR REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Referral to a dermatologist is indicated if the diagnosis of skin lesions is uncertain. Evaluation by a clinician with expertise in the management of endocrine or metabolic disorders is indicated if such disorders are detected.
        </p>
        <p class="headingAnchor" id="H9557805">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Acanthosis nigricans is a common, benign disorder that typically presents with velvety, hyperpigmented plaques on the skin  (
         <a class="graphic graphic_picture graphicRef72964 graphicRef52948 graphicRef66384 graphicRef81693 graphicRef61666" href="/z/d/graphic/72964.html" rel="external">
          picture 1A-E
         </a>
         ). Mucosal involvement is an occasional feature. Individuals of any age may be affected. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – A wide variety of endocrine, metabolic, genetic, and malignant disorders may contribute to the development of acanthosis nigricans. An evaluation for the underlying cause should always be performed:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity is the most common cause of this disorder. Acanthosis nigricans may also be induced by drugs. (See
         <a class="local">
          'Etiology'
         </a>
         above and
         <a class="local">
          'Diagnosis and patient evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malignancy is a rare cause of acanthosis nigricans. In particular, the possibility of an occult malignancy should be considered in adults with extensive or atypical presentations of acanthosis nigricans or new onset acanthosis nigricans of unknown cause. (See
         <a class="local">
          'Malignancy-associated acanthosis nigricans'
         </a>
         above and
         <a class="local">
          'Diagnosis and patient evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Acanthosis nigricans'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Insulin resistance likely plays a key role in many cases of acanthosis nigricans, including cases linked to obesity, diabetes, and some genetic syndromes. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Data are limited on the treatments for acanthosis nigricans:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If an underlying cause is present, treatment or removal of the inciting cause should be attempted. Obesity-related, drug-induced, and malignancy-associated acanthosis nigricans often respond to this form of therapy. The role of agents that improve insulin sensitivity in patients with acanthosis nigricans related to insulin resistance remains uncertain. (See
         <a class="local">
          'Treatment of underlying disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who desire accelerated improvement of acanthosis nigricans or in whom treatment of the underlying disorder is not possible or satisfactory, we suggest a trial of
         <a class="drug drug_general" data-topicid="10014" href="/z/d/drug information/10014.html" rel="external">
          topical tretinoin
         </a>
         or a topical vitamin D analog, such as
         <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">
          calcipotriol
         </a>
         (calcipotriene) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Systemic retinoids may lead to clinical improvement in patients with extensive or severe disease, but relapse is common after treatment discontinuation. (See
         <a class="local">
          'Skin-directed therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27375330">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Kathryn Schwarzenberger, MD, and Inbal Sander, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992; 128:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dassanayake AS, Kasturiratne A, Niriella MA, et al. Prevalence of Acanthosis Nigricans in an urban population in Sri Lanka and its utility to detect metabolic syndrome. BMC Res Notes 2011; 4:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang Y, Woo HY, Sung E, et al. Prevalence of acanthosis nigricans in relation to anthropometric measures: community-based cross-sectional study in Korean pre-adolescent school children. Pediatr Int 2008; 50:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogbera AO, Akinlade A, Ajose O, Awobusuyi J. Prevalence of acanthosis nigricans and its correlates in a cross-section of Nigerians with type 2 diabetes mellitus. Trop Doct 2009; 39:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rafalson L, Eysaman J, Quattrin T. Screening obese students for acanthosis nigricans and other diabetes risk factors in the urban school-based health center. Clin Pediatr (Phila) 2011; 50:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litonjua P, Piñero-Piloña A, Aviles-Santa L, Raskin P. Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes. Endocr Pract 2004; 10:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr 2001; 138:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989; 87:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart CA, Driscoll MS, Lundquist KF, et al. Acanthosis nigricans. J Basic Clin Physiol Pharmacol 1998; 9:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brickman WJ, Binns HJ, Jovanovic BD, et al. Acanthosis nigricans: a common finding in overweight youth. Pediatr Dermatol 2007; 24:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong AS, Williams RL, Smith M, et al. Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in southwestern US primary care practices. Ann Fam Med 2007; 5:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rafalson L, Pham TH, Willi SM, et al. The association between acanthosis nigricans and dysglycemia in an ethnically diverse group of eighth grade students. Obesity (Silver Spring) 2013; 21:E328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong AS, Williams RL, Rhyne R, et al. Acanthosis Nigricans: high prevalence and association with diabetes in a practice-based research network consortium--a PRImary care Multi-Ethnic network (PRIME Net) study. J Am Board Fam Med 2010; 23:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol 2007; 57:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart CA, Gilkison CR, Smith MM, et al. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clin Pediatr (Phila) 1998; 37:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otto DE, Wang X, Tijerina SL, et al. A comparison of blood pressure, body mass index, and acanthosis nigricans in school-age children. J Sch Nurs 2010; 26:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brickman WJ, Huang J, Silverman BL, Metzger BE. Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr 2010; 156:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunaif A, Graf M, Mandeli J, et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flier JS, Eastman RC, Minaker KL, et al. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes 1985; 34:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt TH, Khanijow K, Cedars MI, et al. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome. JAMA Dermatol 2016; 152:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong Z, Huang J, Huang L, et al. Associations of acanthosis nigricans with metabolic abnormalities in polycystic ovary syndrome women with normal body mass index. J Dermatol 2013; 40:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown B, Noonan C, Bentley B, et al. Acanthosis nigricans among Northern Plains American Indian children. J Sch Nurs 2010; 26:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ice CL, Murphy E, Minor VE, Neal WA. Metabolic syndrome in fifth grade children with acanthosis nigricans: results from the CARDIAC project. World J Pediatr 2009; 5:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valery PC, Moloney A, Cotterill A, et al. Prevalence of obesity and metabolic syndrome in Indigenous Australian youths. Obes Rev 2009; 10:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003; 4:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang-Doran I, Savage DB. Congenital syndromes of severe insulin resistance. Pediatr Endocrinol Rev 2011; 8:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berk DR, Spector EB, Bayliss SJ. Familial acanthosis nigricans due to K650T FGFR3 mutation. Arch Dermatol 2007; 143:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002; 147:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz-Pérez MA, Camacho F. Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome. J Eur Acad Dermatol Venereol 2001; 15:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morice-Picard F, Ezzedine K, Delrue MA, et al. Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review. Pediatr Dermatol 2013; 30:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuchi K, Tatsuno K, Matsushita K, et al. Familial acanthosis nigricans with p.K650T FGFR3 mutation. J Dermatol 2018; 45:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad S, Mahmoudi H, Naeem M, Betz RC. Autosomal recessive isolated familial acanthosis nigricans in a Pakistani family due to a homozygous mutation in the insulin receptor gene. Br J Dermatol 2013; 169:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol 1994; 31:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talsania N, Harwood CA, Piras D, Cerio R. Paraneoplastic Acanthosis Nigricans: The importance of exhaustive and repeated malignancy screening. Dermatol Online J 2010; 16:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amjad M, Arfan-ul-Bari, Shah AA. Malignant acanthosis nigricans: an early diagnostic clue. J Coll Physicians Surg Pak 2010; 20:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigel DS, Jacobs MI. Malignant acanthosis nigricans: a review. J Dermatol Surg Oncol 1980; 6:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson SH, Hudson-Peacock M, Muller AF. Malignant acanthosis nigricans: potential role of chemotherapy. Br J Dermatol 1999; 141:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn 2009; 119:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SS, Jung NJ, Im M, et al. Acral-type Malignant Acanthosis Nigricans Associated with Gastric Adenocarcinoma. Ann Dermatol 2011; 23:S208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Long H, Wen H, et al. Image Gallery: Generalized mucosal and cutaneous papillomatosis, a unique sign of malignant acanthosis nigricans. Br J Dermatol 2017; 176:e99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming MG, Simon SI. Cutaneous insulin reaction resembling acanthosis nigricans. Arch Dermatol 1986; 122:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skouby SO. Update on the metabolic effects of oral contraceptives. J Obstet Gynaecol (Lahore) 1986; 6 Suppl 2:S104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology 1994; 189:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mellor-Pita S, Yebra-Bango M, Alfaro-Martínez J, Suárez E. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors. Clin Infect Dis 2002; 34:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane SW, Manoharan S, Mollee PN. Palifermin-induced acanthosis nigricans. Intern Med J 2007; 37:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee M, Grassi M. Acanthosis nigricans in a patient treated with palifermin. Cutis 2010; 86:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karadag A, Kavala M, Demir F, et al. A case of hyperpigmentation and acanthosis nigricans by testosterone injections. Hum Exp Toxicol 2014; 33:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manu P, Al-Dhaher Z, Dargani N, Correll CU. Acanthosis nigricans during treatment with aripiprazole. Am J Ther 2014; 21:e90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirai H, Hamada J, Hasegawa K, Ishii E. Acanthosis nigricans in a Japanese boy with hypochondroplasia due to a K650T mutation in FGFR3. Clin Pediatr Endocrinol 2017; 26:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hida Y, Kubo Y, Nishio Y, et al. Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3. Acta Derm Venereol 2009; 89:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haase I, Hunzelmann N. Activation of epidermal growth factor receptor/ERK signaling correlates with suppressed differentiation in malignant acanthosis nigricans. J Invest Dermatol 2002; 118:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koyama S, Ikeda K, Sato M, et al. Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol 1997; 32:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeong JS, Lee JY, Yoon TY. Unilateral nevoid acanthosis nigricans with a submammary location. Ann Dermatol 2011; 23:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnaram AS. Unilateral nevoid acanthosis nigricans and neurofibromatosis 1: an unusual association. Indian J Dermatol Venereol Leprol 2010; 76:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Waal AC, van Rossum MM, Bovenschen HJ. Extensive segmental acanthosis nigricans form of epidermal nevus. Dermatol Online J 2010; 16:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ersoy-Evans S, Sahin S, Mancini AJ, et al. The acanthosis nigricans form of epidermal nevus. J Am Acad Dermatol 2006; 55:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RA. Acral acanthotic anomaly (AAA). J Am Acad Dermatol 1981; 5:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RA. Acral acanthosis nigricans (acral acanthotic anomaly). J Am Acad Dermatol 2007; 56:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brantsch KD, Moehrle M. Acanthosis nigricans in a patient with sarcoma of unknown origin. J Am Acad Dermatol 2010; 62:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas M, Radhakrishnan S, Sunny B, et al. Malignant acanthosis nigricans with occult primary. Indian J Dermatol Venereol Leprol 2002; 68:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pentenero M, Carrozzo M, Pagano M, Gandolfo S. Oral acanthosis nigricans, tripe palms and sign of leser-trélat in a patient with gastric adenocarcinoma. Int J Dermatol 2004; 43:530.
          </a>
         </li>
         <li class="breakAll">
          Weedon D. Miscellaneous conditions. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.501.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall JM, Moreland A, Cox GJ, Wade TR. Oral acanthosis nigricans: report of a case and comparison of oral and cutaneous pathology. Am J Dermatopathol 1988; 10:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J 2008; 14:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petit A, Lemarchand-Venencie F, Pinquier L, et al. [Nevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal nevus): three cases]. Ann Dermatol Venereol 2012; 139:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsabal M, Cogrel O, Caumont C, et al. Mosaic mutations in FGFR3 and FGFR2 are associated with naevoid acanthosis nigricans or RAVEN (round and velvety epidermal naevus). Br J Dermatol 2019; 180:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bessis D, Petit A, Battistella M, et al. Naevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal naevus) and mosaic FGFR3 and FGFR2 mutations. Br J Dermatol 2019; 180:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins HW, Jenkins J, Horn TD, Kroumpouzos G. Pregnancy-associated hyperkeratosis of the nipple: a report of 25 cases. JAMA Dermatol 2013; 149:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romo A, Benavides S. Treatment options in insulin resistance obesity-related acanthosis nigricans. Ann Pharmacother 2008; 42:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuroki R, Sadamoto Y, Imamura M, et al. Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Dermatology 1999; 198:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novotny R, Davis J, Butel J, et al. Effect of the Children's Healthy Living Program on Young Child Overweight, Obesity, and Acanthosis Nigricans in the US-Affiliated Pacific Region: A Randomized Clinical Trial. JAMA Netw Open 2018; 1:e183896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermanns-Lê T, Hermanns JF, Piérard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002; 19:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N, et al. Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. J Drugs Dermatol 2006; 5:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tankova T, Koev D, Dakovska L, Kirilov G. Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract 2002; 56:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walling HW, Messingham M, Myers LM, et al. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol 2003; 2:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasniewska M, Arrigo T, Crisafulli G, et al. Recovery of acanthosis nigricans under prolonged metformin treatment in an adolescent with normal weight. J Endocrinol Invest 2009; 32:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee PJ, Cranston I, Amiel SA, et al. Effect of metformin on glucose disposal and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans. Horm Res 1997; 48:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giri D, Alsaffar H, Ramakrishnan R. Acanthosis Nigricans and Its Response to Metformin. Pediatr Dermatol 2017; 34:e281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sett A, Pradhan S, Sancheti K, et al. Effectiveness and Safety of Metformin versus Canthex™ in Patients with Acanthosis Nigricans: A Randomized, Double-blind Controlled Trial. Indian J Dermatol 2019; 64:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis DL, Kafka SP, Chow JC, et al. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 1987; 317:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassilopoulou-Sellin R, Cangir A, Samaan NA. Acanthosis nigricans and severe insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy. Am J Clin Oncol 1992; 15:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh JS, Munn SE, Plunkett TA, et al. Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol 2000; 42:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebria MM, Belinson J, Kim R, Mekhail TM. Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol 2006; 101:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunetta M, Di Mauro M, Le Moli R, Burrafato S. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J Endocrinol Invest 1996; 19:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherertz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol 1988; 124:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treesirichod A, Chaithirayanon S, Wongjitrat N. Comparison of the efficacy and safety of 0.1% adapalene gel and 0.025% tretinoin cream in the treatment of childhood acanthosis nigricans. Pediatr Dermatol 2019; 36:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol 1991; 127:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger BJ, Gross PR. Another use for tretinoin--pseudoacanthosis nigricans. Arch Dermatol 1973; 108:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis 2003; 71:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adigun CG, Pandya AG. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. J Eur Acad Dermatol Venereol 2009; 23:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böhm M, Luger TA, Metze D. Treatment of mixed-type acanthosis nigricans with topical calcipotriol. Br J Dermatol 1998; 139:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregoriou S, Anyfandakis V, Kontoleon P, et al. Acanthosis nigricans associated with primary hypogonadism: successful treatment with topical calcipotriol. J Dermatolog Treat 2008; 19:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbach A, Ram R. Treatment of Acanthosis nigricans of the axillae using a long-pulsed (5-msec) alexandrite laser. Dermatol Surg 2004; 30:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichiyama S, Funasaka Y, Otsuka Y, et al. Effective treatment by glycolic acid peeling for cutaneous manifestation of familial generalized acanthosis nigricans caused by FGFR3 mutation. J Eur Acad Dermatol Venereol 2016; 30:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldissera RL, Yang EJ, Schmitt JV, et al. Trichloroacetic acid peels for the treatment of acanthosis nigricans. J Am Acad Dermatol 2022; 86:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treesirichod A, Chaithirayanon S, Chaikul T, Chansakulporn S. The randomized trials of 10% urea cream and 0.025% tretinoin cream in the treatment of acanthosis nigricans. J Dermatolog Treat 2021; 32:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leerapongnan P, Jurairattanaporn N, Kanokrungsee S, Udompataikul M. Comparison of the effectiveness of fractional 1550-nm erbium fiber laser and 0.05% tretinoin cream in the treatment of acanthosis nigricans: a prospective, randomized, controlled trial. Lasers Med Sci 2020; 35:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swineford SL, Drucker CR. Palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis with retinoids. J Drugs Dermatol 2010; 9:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz RA. Treatment of acanthosis nigricans with oral isotretinoin. Arch Dermatol 1980; 116:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnekoh B, Thiele B, Merk H, Mahrle G. [Systemic photochemotherapy (PUVA) in acanthosis nigricans maligna: regression of keratosis, hyperpigmentation and pruritus]. Z Hautkr 1989; 64:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenwood R, Tring FC. Treatment of malignant acanthosis nigricans with cyproheptadine. Br J Dermatol 1982; 106:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malisiewicz B, Boehncke S, Lang V, et al. Epidermal insulin resistance as a therapeutic target in acanthosis nigricans? Acta Derm Venereol 2014; 94:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CURTH HO, HILBERG AW, MACHACEK GF. The site and histology of the cancer associated with malignant acanthosis nigricans. Cancer 1962; 15:364.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13754 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1626961" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevalence and significance of acanthosis nigricans in an adult obese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21276250" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence of Acanthosis Nigricans in an urban population in Sri Lanka and its utility to detect metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19261117" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevalence of acanthosis nigricans in relation to anthropometric measures: community-based cross-sectional study in Korean pre-adolescent school children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19762579" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence of acanthosis nigricans and its correlates in a cross-section of Nigerians with type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21727074" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Screening obese students for acanthosis nigricans and other diabetes risk factors in the urban school-based health center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15256325" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11295708" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2773965" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prevalence of acanthosis nigricans in an unselected population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10212845" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18035980" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acanthosis nigricans: a common finding in overweight youth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17548847" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in southwestern US primary care practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23592686" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The association between acanthosis nigricans and dysglycemia in an ethnically diverse group of eighth grade students.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20616290" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acanthosis Nigricans: high prevalence and association with diabetes in a practice-based research network consortium--a PRImary care Multi-Ethnic network (PRIME Net) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17592743" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Juvenile acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9492114" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20335230" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A comparison of blood pressure, body mass index, and acanthosis nigricans in school-age children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796772" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acanthosis nigricans identifies youth at high risk for metabolic abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3305551" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3881301" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26720591" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23289590" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Associations of acanthosis nigricans with metabolic abnormalities in polycystic ovary syndrome women with normal body mass index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20595701" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acanthosis nigricans among Northern Plains American Indian children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19172328" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Metabolic syndrome in fifth grade children with acanthosis nigricans: results from the CARDIAC project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19207873" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prevalence of obesity and metabolic syndrome in Indigenous Australian youths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12688837" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cutaneous manifestations of endocrine disorders: a guide for dermatologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21525795" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Congenital syndromes of severe insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17875876" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Familial acanthosis nigricans due to K650T FGFR3 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12452857" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Genes, growth factors and acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11730043" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24283439" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29068064" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Familial acanthosis nigricans with p.K650T FGFR3 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23448340" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Autosomal recessive isolated familial acanthosis nigricans in a Pakistani family due to a homozygous mutation in the insulin receptor gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8021347" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20804685" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Paraneoplastic Acanthosis Nigricans: The importance of exhaustive and repeated malignancy screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20378042" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Malignant acanthosis nigricans: an early diagnostic clue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6257767" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Malignant acanthosis nigricans: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10583123" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Malignant acanthosis nigricans: potential role of chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19514649" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22148052" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Acral-type Malignant Acanthosis Nigricans Associated with Gastric Adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28504375" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Image Gallery: Generalized mucosal and cutaneous papillomatosis, a unique sign of malignant acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3527077" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cutaneous insulin reaction resembling acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12315275" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Update on the metabolic effects of oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8075456" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acanthosis nigricans caused by nicotinic acid: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11823959" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17535389" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Palifermin-induced acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21049730" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Acanthosis nigricans in a patient treated with palifermin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24505054" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A case of hyperpigmentation and acanthosis nigricans by testosterone injections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23011171" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Acanthosis nigricans during treatment with aripiprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29026271" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Acanthosis nigricans in a Japanese boy with hypochondroplasia due to a K650T mutation in FGFR3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19688170" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11982771" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Activation of epidermal growth factor receptor/ERK signaling correlates with suppressed differentiation in malignant acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058298" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21738374" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Unilateral nevoid acanthosis nigricans with a submammary location.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21079328" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Unilateral nevoid acanthosis nigricans and neurofibromatosis 1: an unusual association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20579462" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Extensive segmental acanthosis nigricans form of epidermal nevus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010754" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The acanthosis nigricans form of epidermal nevus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7263979" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Acral acanthotic anomaly (AAA)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17224380" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Acral acanthosis nigricans (acral acanthotic anomaly).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20159329" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Acanthosis nigricans in a patient with sarcoma of unknown origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17657010" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Malignant acanthosis nigricans with occult primary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15230897" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Oral acanthosis nigricans, tripe palms and sign of leser-trélat in a patient with gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15230897" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Oral acanthosis nigricans, tripe palms and sign of leser-trélat in a patient with gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3177823" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Oral acanthosis nigricans: report of a case and comparison of oral and cutaneous pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19061584" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Acanthosis nigricans: a practical approach to evaluation and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22401682" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : [Nevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal nevus): three cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30117157" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Mosaic mutations in FGFR3 and FGFR2 are associated with naevoid acanthosis nigricans or RAVEN (round and velvety epidermal naevus).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30580445" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Naevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal naevus) and mosaic FGFR3 and FGFR2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23616176" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Pregnancy-associated hyperkeratosis of the nipple: a report of 25 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18492785" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Treatment options in insulin resistance obesity-related acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10325466" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2642485" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30646266" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Effect of the Children's Healthy Living Program on Young Child Overweight, Obesity, and Acanthosis Nigricans in the US-Affiliated Pacific Region: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11860562" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Juvenile acanthosis nigricans and insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17039655" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12425366" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Therapeutic approach in insulin resistance with acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14711151" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Improvement of acanthosis nigricans on isotretinoin and metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19494716" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Recovery of acanthosis nigricans under prolonged metformin treatment in an adolescent with normal weight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9251926" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of metformin on glucose disposal and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28758315" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Acanthosis Nigricans and Its Response to Metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30983607" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Effectiveness and Safety of Metformin versus Canthex™in Patients with Acanthosis Nigricans: A Randomized, Double-blind Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2825016" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1590285" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Acanthosis nigricans and severe insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10640933" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16443260" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9007703" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3389852" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30883877" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Comparison of the efficacy and safety of 0.1% adapalene gel and 0.025% tretinoin cream in the treatment of childhood acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863071" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Treatment of acanthosis nigricans with tretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4716734" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Another use for tretinoin--pseudoacanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12553628" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18721216" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9893209" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Treatment of mixed-type acanthosis nigricans with topical calcipotriol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18608738" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Acanthosis nigricans associated with primary hypogonadism: successful treatment with topical calcipotriol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15274711" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Treatment of Acanthosis nigricans of the axillae using a long-pulsed (5-msec) alexandrite laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26818779" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Effective treatment by glycolic acid peeling for cutaneous manifestation of familial generalized acanthosis nigricans caused by FGFR3 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33516770" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Trichloroacetic acid peels for the treatment of acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31868565" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : The randomized trials of 10% urea cream and 0.025% tretinoin cream in the treatment of acanthosis nigricans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31953736" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Comparison of the effectiveness of fractional 1550-nm erbium fiber laser and 0.05% tretinoin cream in the treatment of acanthosis nigricans: a prospective, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20865850" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis with retinoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7352756" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Treatment of acanthosis nigricans with oral isotretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2561241" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : [Systemic photochemotherapy (PUVA) in acanthosis nigricans maligna: regression of keratosis, hyperpigmentation and pruritus].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7082574" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Treatment of malignant acanthosis nigricans with cyproheptadine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24514457" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Epidermal insulin resistance as a therapeutic target in acanthosis nigricans?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13882755" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The site and histology of the cancer associated with malignant acanthosis nigricans.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
